Cel-Sci (NYSEAMERICAN:CVM) Trading Up 1% – Here’s What Happened

Shares of Cel-Sci Corporation (NYSEAMERICAN:CVM) were up 1% during mid-day trading on Tuesday . The company traded as high as $1.0450 and last traded at $1.02. 189,884 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 335,736 shares. The stock had previously closed at $1.01.

Cel-Sci Stock Down 2.1%

The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64. The company has a market cap of $17.03 million, a P/E ratio of -0.10 and a beta of 0.54. The company has a fifty day moving average of $1.96 and a 200 day moving average of $3.79.

Cel-Sci (NYSEAMERICAN:CVM) last posted its earnings results on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Investors Weigh In On Cel-Sci

Several hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE bought a new position in shares of Cel-Sci in the 3rd quarter worth approximately $80,000. HighTower Advisors LLC bought a new stake in Cel-Sci during the fourth quarter valued at approximately $53,000. HRT Financial LP purchased a new stake in Cel-Sci during the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new stake in Cel-Sci during the fourth quarter valued at approximately $66,000. Finally, Renaissance Technologies LLC bought a new position in Cel-Sci in the fourth quarter worth approximately $81,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.